In Japan, three classes of bDMARDs have been available in the clinical practice of RA (anti-TNF since 2013, anti-IL-6R since 2008, and CTLA4-Ig since 2011)16–18. The gene discussed is CTLA4; the disease is rheumatoid arthritis.